Status:
RECRUITING
A Survey of Lanadelumab in Participants with Hereditary Angioedema
Lead Sponsor:
Takeda
Conditions:
Hereditary Angioedema (HAE)
Eligibility:
All Genders
Brief Summary
This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instru...
Eligibility Criteria
Inclusion
- Inclusion Criteria - Participants diagnosed with hereditary angioedema (HAE) and treated with Lanadelumab for the first time.
- Exclusion Criteria
- \- None
Exclusion
Key Trial Info
Start Date :
May 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05397431
Start Date
May 30 2022
End Date
January 31 2026
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Takeda selected site
Tokyo, Tokyo, Japan